In this segment the panelist reviews the baseline patient and disease characteristics across the three treatment arms in MARIPOSA-2.
Osimertinib Shows Sustained Survival Benefit in EGFR-Mutant NSCLC
The safety profiles of osimertinib monotherapy and combination therapy were consistent with prior reports in EGFR-mutated non–small cell lung cancer.
Navigating Management and Dosing Considerations for Amivantamab in NSCLC
Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.
Prioritizing Climate Hazard Preparedness Following NSCLC Surgery
Leticia Nogueira, PhD, MPH, highlights how facilities exposed to wildfires tend to have longer lengths of stay for patients undergoing surgery for NSCLC.
Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology
Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.
Ensartinib Yields “Promising” Efficacy in Pretrated METex14–positive NSCLC
In the phase 2 EMBRACE trial, ensartinib demonstrated an ORR of 53.3%, a DCR of 86.7%, and a tumor shrinkage rate of 33.3% in patients with METex14-positive NSCLC.
Selpercatinib Demonstrates Durable Responses in RET Fusion–Positive NSCLC
In patients who were pretreated and treatment naïve with RET fusion-positive NSCLC, selpercatinib yielded an ORR of 61.5% and 82.6%, respectively.